FindTrial
Sign In

Phase II/III Study of S-877503 in Pediatric Patients with Attention-deficit/Hyperactivity Disorder -Long term Extension Study-

Phase II/III Study of S-877503 in Pediatric Patients with Attention-deficit/Hyperactivity Disorder -Long term Extension Study-

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222071
Enrollment
Unknown
Registered
2013-05-08
Start date
2013-05-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-deficit/Hyperactivity Disorder

Interventions

investigational material(s) Generic name etc : S-877503 INN of investigational material : Therapeutic category code : 117 Psychotropic agents Dosage and Administration for Investigational material :

Sponsors

SHIONOGI & CO., LTD.
Lead Sponsor
Shire Development LLC
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient has completed 9-week administration and the last examination at Visit 9 in the preceding study of S-877503 in pediatric patients with ADHD. And et al.

Exclusion criteria

Exclusion criteria: 1) Patient has complications such as serious hepatic disorder, renal disorder, heart disease, lung disease, hematological disease, and metabolic disease. 2) Patient considered a suicide risk. And et al.

Design outcomes

Primary

MeasureTime frame
Safety—

Contacts

Public ContactContact for Clinical Trial Information

Takeda Pharmaceutical Company Limited

smb.Japanclinicalstudydisclosure@takeda.com+81-6-6204-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026